SEC Form 4 · accession 0001171000-15-000043
Nexvet Biopharma plc · NVET
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Colin Giles
Officer — VP Clinical&Regulatory Affairs
Period of report
Jul 1, 2015
Accepted (ET)
Jul 2, 2015 · 1:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618561
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Jul 1, 2015 | M | 2,098 | $0.125 | A | 17,890 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF1 | $0.125 | Jul 1, 2015 | M | 2,098 | D | Jul 1, 2015 | Jul 1, 2019 | Ordinary Shares | 2,098 | 7,343 | D |
Explanation of responses
- F12,098 Restricted Share Units vested and became convertible on 7/1/15 and 2,098 Restricted Share Units will vest and be convertible on each of 7/1/16 and 7/1/17; The remaining 3,147 Restricted Share Units will vest and be convertible on 12/31/15.